Which groundbreaking pharmaceutical product launch strategy involved patients in the development process, leading to the first FDA-approved treatment for spinal muscular atrophy (SMA) in 2016?

In the highly regulated world of medicine, product launches require extensive planning, clinical trials, and regulatory approvals. Some medical innovations transform treatment paradigms while others quietly revolutionize healthcare delivery. This poll tests your knowledge about a significant pharmaceutical product launch that changed the standard of care for millions of patients worldwide. Can you identify the correct timeline and approach that led to this groundbreaking success?

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Spinraza (nusinersen): Biogen collaborated with patient advocacy groups throughout clinical trials and created an expanded access program before approval
Ocrevus (ocrelizumab): Roche used a phased rollout strategy focusing first on neurologists before expanding to primary care physicians
Keytruda (pembrolizumab): Merck employed a tumor-agnostic approval strategy that bypassed traditional patient involvement
Entresto (sacubitril/valsartan): Novartis launched with a value-based pricing model but excluded patient advocacy input during development